Introduction
Breast cancer continues to be a leading cause for cancerrelated death in women across the globe. Mammaglobin-A (Mam-A), a 10 kDa human breast cancer-associated antigen initially identified by Watson and Fleming [1] , offers a novel immunotherapeutic target. The Mam-A is expressed almost exclusively in 80 % of primary and metastatic breast cancers [1] [2] [3] [4] [5] [6] . This specificity, as well as wide Mam-A expression in breast cancers, makes it an attractive target for vaccination. We demonstrated that passive transfer of T cells from Mam-A-vaccinated HLA-A2/hCD8 double transgenic mice into human breast cancer-implanted NOD/SCID mice resulted in significant reduction of tumor size in a HLA-A2-and Mam-A-specific manner [7] . Based on these encouraging results, we are currently conducting a phase I clinical trial of a Mam-A cDNA vaccination in breast cancer patients with stage-IV metastatic disease.
Enhanced understanding on the role for the innate and adaptive immune systems in controlling the development of malignancies has been established over the past several years [8] [9] [10] . Progress in the identification of tumor antigens, and elucidation of antigen presenting pathways and effector mechanisms have renewed interest in vaccine therapy for cancer. Immunological analysis following DNA vaccination for the most part has been restricted either toward the induction of antibodies or generation of tumor-specific CD8? T cells [11, 12] . Therefore, currently there is very little information available regarding the impact of cDNA vaccination on tumor-specific CD4? T cell responses.
Inducible co-stimulator (ICOS) molecules are expressed on the newly activated T cells [13] and in vitro functional studies have demonstrated that ICOS is a potent costimulatory molecule related to B7/CD28 family [14, 15] . Miller et al. [16] have demonstrated that tumor-infiltrating CD4?CD25? regulatory T cells (Treg) accumulating in prostate tumors express higher levels of ICOS than Treg in the peripheral blood. Recent studies have shown that anti-CTLA-4 treatment of prostate cancer patients can increase the frequency of CD4?ICOS hi T cells [17] accompanied by a shift in the ratio of effector to Treg cells, thus improving the clinical outcome. In this article, we provide evidence that following Mam-A cDNA vaccination of breast cancer patients, there is an increased frequency of cytotoxic IFN-c-secreting CD4?ICOS hi T cells strongly suggesting that this novel immunotherapeutic approach will be beneficial for the treatment of breast cancer.
Experimental methods

Phase I clinical trial
We have recently initiated a phase I clinical trial of a Mam-A DNA vaccine at Washington University School of Medicine. Seven HLA-A2? patients with metastatic breast cancer treated with the Mam-A DNA vaccine were available for the correlative studies described in this article. The vaccine was administered on days 0, 28, and 56. Nine normal multiparous women were included in the study following informed consent as a negative control. Another set of patients used as a negative control were the prevaccinated patients. As the stage-IV metastatic breast cancer has a long disease course, a separate cohort of patients for negative control studies was not available during this study. Peripheral blood specimens were obtained before vaccination and at serial time points after vaccination. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by Ficoll-Hypaque density gradient centrifugation (Pharmacia, Uppasala, Sweden) and stored at -135°C until evaluation [18] . The CD4? T cells were isolated from PBMC by positive selection using a MACS bead isolation kit (Miltenyi Biotec Inc., CA).
ELISpot assay
Frozen PBMCs were cultured overnight in complete RPMI-1640 and viability was determined by trypan blue exclusion [19] . PBMCs with viability of at least 90 % were used for ELISpot analysis. CD4? T cells were enriched by MACS bead separation negative selection using immunomagnetic separation cocktails (Stem cell Technologies, Canada). These enriched CD4? T cells (3 9 10 5 , [90 % purity) were cultured in triplicate in the presence of CD3 monoclonal antibody (mAb) (1 lg/mL) and IL-2 (1 lg/ mL) for non-specific stimulation or purified Mam-A protein (20 lg/mL) on the 96-well ELISpot plates (Multiscreen IP plate, Millipore, MA) pre-coated with IFN-c mAb (4 lg/mL) or IL-10 mAb (4 lg/mL) in the presence of autologous-irradiated CD4-depleted PBMCs as antigenpresenting cells (APCs) (3 9 10 4 ) in the complete RPMI-1640 medium. Cultures were placed for 48-72 h in humidified 5 % CO 2 incubator at 37°C for IFN-c or IL-10. The plates were washed and developed to detect the number of spots in individual wells using an ImmunoSpot analyzer (Cellular Technology, Shaker Heights, OH). CD4? T cells plus autologous APCs cultured in medium without antigens were used as negative controls, while CD4? T cells plus autologous APCs cultured with PHA (5 lg/mL) were used as positive controls. A number of spots in negative controls subtracted from spots in experimental wells were reported in the final results as spots per million cells (spm ± SEM).
Flow cytometry
Abs used for flow cytometry consisted of CD3-FITC, CD4-PerCP/Cy5.5 (BD PharMingen), CD25-PE, FoxP3-PE (eBiosciences, San Diego, CA), and biotinylated ICOS (eBiosciences) conjugated with streptavidin-APCCy7 (BD Biosciences, San Diego, CA). Intracellular staining for FoxP3 was conducted as per the manufacturer's guidelines. Samples were analyzed using a FACS Calibur/LSRII flow cytometer (Becton-Dickinson, Franklin Lakes, NJ), and cell sorting was performed using a Vantage cell sorter (Becton-Dickinson, Franklin Lakes, NJ). Data were analyzed using BD FACSDiva software. Gates were set according to isotype controls.
RT-PCR
Expression profiles of intracellular signal genes in the CD4? T cells isolated from PBMCs were analyzed using the FAM-labeled quantitative real-time PCR (RT-PCR) primers for IL-10, IFN-c, T-bet, and FoxP3 (Applied Biosystems, Foster City, CA) as per the manufacturer's recommendation. In brief, total RNA was extracted from 10 6 cells using TRIzol reagent (Sigma-Aldrich, St. Louis, MO). The RNA was reverse transcribed and RT-PCR was performed in a final reaction volume of 20 lL using iCycler 480 Probes Master (Roche Diagnostics, Indianapolis, IN). Each sample was analyzed in triplicate. Cycling conditions consisted of an initial denaturation at 95°C for 15 min, followed by 40 cycles of 95°C for 30 s, and then followed by 61°C for 1 min.
Breast cancer cell lines
The breast cancer cell lines, AU-565 (Mam-A?) and MCF-7 (Mam-A-) [20, 21] , were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Breast cancer cell lines were cultured in RPMI-1640 culture medium at 37°C in 5 % CO 2 incubator until they reached an optimal 80 % confluency. The presence of Mam-A in the cell lines were determined by reverse transcriptasepolymerase chain reaction and western blot analysis.
Cytotoxicity assay
Ability of T cells to lyse the target cells was investigated by LDH cytotoxicity assay (Promega, Madison, WI) [22] . Breast cancer cells (5 9 10 3 cells) in 100 lL of complete medium were plated in triplicate cultures in round bottom 96-well plates in the presence of varying numbers of CD4?ICOS hi T cells (6.25:1 to 50:1) and incubated at 37°C in a humidified 5 % CO 2 incubator for 4 h. Controls were breast cancer target cells alone or CD4?ICOS hi T cells isolated from normal subjects. Maximal release was determined by adding Triton X-100 (1 %) to the target cells. A colorimetric measurement of the released LDH was developed as per manufacturer's protocol and measured using UV/Visible spectrophotometer at 450 nm. The percentage-specific lysis was calculated using the formula [(experimental LDH release -spontaneous LDH release)/(maximum LDH release -spontaneous LDH release)] 9 100. Cold target inhibition analyses were performed to determine the Mam-A specificity with the addition of Mam-A protein (1-1,000 ng/mL) to culture medium and subsequent LDH release.
Statistical analysis
Graphpad Prism version 4.03 software (GraphPad Software Inc., CA) was utilized. Mann-Whitney test assessed differences in CD4? T cell responses specific to individual antigens between two groups (pre-and post-vaccination). Correlation analysis was performed using Spearman rank test. Two-sided level of significance was set at p \ 0.05, and results were expressed in mean ± standard error of mean.
Results
Increased frequency of CD4?FoxP3? T cells in the circulation of breast cancer patients
We used the FoxP3 expression on CD4? T cells to determine the frequency of Treg in breast cancer patients [23] . As shown in Fig. 1 , the frequency of CD4?FoxP3? T cells was significantly increased (p \ 0.05) in breast cancer patients (n = 7) in comparison to normal subjects (19 ± 6 vs 7 ± 3 % in normals [n = 9]). However, the subset of Tregs which expresses ICOS in the breast cancer patients (21 ? 5 %) remained similar to the normals (21 ± 6 %). The frequency of ICOS in CD4? T cells in breast cancer patients (7 ± 3 %) was slightly higher than the normal subjects (4 ± 2 %), which did not reach statistical significance (p = 0.67).
Increased frequency of CD4?ICOS hi T cells following Mam-A vaccination
ICOS is expressed in two (Th1 and Th2) subsets of CD4? T cells, including Treg [24] , and the newly activated naïve CD4? T cells [25] . To evaluate T cell activation following Mam-A vaccination, the frequency of CD4? T cells with ICOS hi frequency was determined using flow cytometry. As shown in Fig. 2a , following Mam-A cDNA vaccination within a period of 6 months, the frequency of CD4?I-COS hi T cells increased from 7 ± 3 to 23 ± 4 %. In contrast, the frequency of Treg (CD4?FoxP3?) cells decreased (Fig. 2b) Furthermore, mRNA expression profile in the unstimulated CD4? T cells reveals increased expression of IFNc (normal: 3 ± 0.8 fold; breast cancer: 2.5 ± 0.7 fold; and following Mam-A vaccine: 8.6 ± 2.4 fold, p = 0.003) and effector Th1 lineage marker T-bet (normal: 6.2 ± 2.5 fold; breast cancer: 5.1 ± 1.7 fold; and following Mam-A vaccine: 13.1 ± 3.4 fold, p = 0.012). There is also a decreased expression of IL-10 (normal: 16.2 ± 4.3 fold; breast cancer: 32.7 ± 7.6 fold; and following Mam-A vaccine: 14.4 ± 5.1 fold, p = 0.001) and FoxP3 (normal: 4.1 ± 0.9 fold; breast cancer: 14.5 ± 4.9 fold; and following Mam-A vaccine: 7.9 ± 3.1 fold, p = 0.0048). This confirms our previous results with nonspecific stimulation with anti-CD-3/IL-2 which demonstrated that following Mam-A vaccination, there was a shift toward cytotoxic Th-response along with an increased IFN-c secretion.
Induction of Mam-A-specific IFN-c responses following vaccination
To determine the specificity of IFN-c responses to Mam-A protein, cytokine responses of CD4? T cells specific for Mam-A protein were determined by ELISpot. The CD4? T cells were incubated for 48-72 h in the presence of Mam-A whole protein or human albumin (control) along with autologous irradiated CD4-depleted PBMCs. ELISpot assay was performed to determine the Mam-A-specific frequency of IFN-c-and IL-10-producing CD4? T cells. As shown in Fig. 4a , following vaccination the breast cancer patients had markedly enhanced IFN-c responses specific to Mam-A protein (normal/control: 8 ± 4 spm; breast cancer: 10 ± 6 spm; and following Mam-A vaccine: 72 ± 23 spm, p = 0.0001). In contrast, the IL-10 responses specific to Mam-A significantly (Fig. 4b) [20, 21] . As shown in Fig. 6 , co-culture of CD4?ICOS hi T cells (collected from breast cancer patients following vaccination) with AU-565 breast cancer cell line (Mam-A?) resulted in significant cytotoxicity (46 ± 12 vs 2 ± 1 %, p \ 0.001). This was specific to Mam-A since no increase in cytotoxicity was noted with a 
Discussion
The activation and expansion of immune T cells are tightly controlled by transmembrane ligand/receptor signals [26] . In 1999, Hutloff et al. [27] demonstrated the expression of ICOS on CD4? T cells using antibodies produced against activated human T cells. Sequence analysis also demonstrated 39 % homology to human CD28 [27] . ICOS is a T cell-specific surface molecule related to B7 family along with CD28 and CTLA-4. Although ICOS is expressed at low levels on resting naïve T cells, it is rapidly upregulated following T cell receptor ligation and CD28 costimulation [28] . In vivo studies using ICOS-knock-out mice demonstrated that these animals were incapable of controlling viral or parasitic infections due to impaired Th1 and Th2 responses, respectively [29] . Bladder cancer patients following anti-CTLA-4 monoclonal therapy demonstrated increased frequency of ICOS hi in CD4? T cells in peripheral blood and tumor tissue microenvironment [30] . Furthermore, these ICOS hi subfraction of CD4? T cells upon restimulation induced significantly increased levels of IFN-c, thus suggesting effector functions for the ICOS hiexpressing T cells.
Successful cancer-specific immunotherapy is based on the identification of tumor-specific antigens and their epitopes for both CD4 and CD8 T cells. The ability of DNA vaccines and CpG oligo-deoxynucleotides to preferentially generate Th1 responses in mouse models has been shown to be useful in prevention and/or treatment of intracellular infections [31] . We have previously demonstrated that Mam-A cDNA vaccination of HLA-A/hCD8 double transgenic animals induced specific T cells which upon passive transfer resulted in tumor regression of human breast cancer tumors growing in SCID mice [7] . Based on this pre-clinical study, we have recently initiated a phase I clinical trial to study the safety and efficacy of Mam-A cDNA vaccination of breast cancer patients with stage-IV metastasis. In this article, we present our preliminary results demonstrating that Mam-A cDNA vaccination resulted in eliciting a strong CD4 cellular effector immune responses with antigen-specific cytotoxicity.
TICOS has been shown to be expressed on the newly activated CD4, CD8, and Treg cell populations [32] . A higher frequency of Treg has been seen in melanoma [33] , prostate [16] , and bladder cancers [30] and were implicated in evasion of immune system favoring continued growth of the tumors. We demonstrate in this article that FoxP3? -Treg frequency is higher in breast cancer patients (19 ± 6 vs 7 ± 3 % in normal subjects, Fig. 1 ) and more importantly, our results clearly indicate that following Mam-A vaccination, there is a significant decrease in the Treg frequency (19 ± 6 vs 10 ± 5 %), although not statistically significant possibly due to small number of patients analyzed so far. Our results also demonstrate that ICOS expression on CD4?CD25? Tregs remained constant (approximately 21 %) in breast cancer patients before and after vaccination similar to that seen in normal subjects. However, the CD4?ICOS hi frequency significantly increased following vaccination of breast cancer patients from 7 ± 3 to 23 ± 4 %. Furthermore, the ratio of CD4?ICOS hi to Tregs also increased from 0.37 ± 0.12 to 2.3 ± 0.72 (Fig. 2) . This strongly demonstrates that following Mam-A vaccination, there is increased activation of all populations of CD4? T cells. The ELISpot assay demonstrated that these are Th1/IFN-c releasing CD4? T cells (Fig. 3 ) with significant decrease in Th2/IL-10 frequency. This is also confirmed by mRNA expression analysis, where in increased expression of T-bet, a Th1-specific molecule was noted. These results support the conclusion that Mam-A vaccination results in the expansion of Th1 immunity.
The CD4? T cells were traditionally considered to be a helper cell population which contribute to cytolytic action through augmenting CD8? T cell activity. However, studies from our laboratory [34] and others [35] have demonstrated direct cytotoxic effector functions for human CD4? T cells resulting in specific cytotoxicity mediated by perforin and granzyme. In addition, there are articles demonstrating that cytotoxic phenotype of T-helper subsets (Th1/IFN-c) correlates with ICOS expression [36] . Quiroga et al. [37] demonstrated that ICOS activation promotes the induction of Th1/IFN-c cytokine responses against mycobacterium tuberculosis, an intracellular bacterial pathogens. These results are in agreement with our data which demonstrates that the newly activated CD4?ICOS hi T cells releasing IFN-c which were also cytotoxic in vitro to breast cancer cell lines expressing Mam-A protein with HLA class I (HLA-A2) restriction (Figs. 5, 6 ). However, if these cells are involved in vivo in the direct tumor cytotoxic activity to breast cancer cells, following Mam-A vaccination needs to be established. Our data is in agreement with the finding of Chen et al. [17] , who demonstrated increased frequency cytotoxic IFN-c producing CD4?ICOS hi T cells in prostate cancer patients following anti-CTLA-4 therapy.
In conclusion, data presented in this manuscript demonstrate that following Mam-A DNA vaccination, there is a specific expansion of IFN-c producing CD4?ICOS hi T cells with the ability to specifically lyse breast cancer cells expressing Mam-A. These results are encouraging and supporting the potential use of Mam-A DNA vaccination as a novel therapeutic strategy for treatment of breast cancer. Our studies, along with other published findings, also suggest that ICOS expression may be employed as a surrogate marker of antitumor response following immune therapy.
